Site sustainability is the pressure point that keeps coming up in clinical operations, and it lands with numbers: in 2025, 35% of clinical research sites named trial complexity their top challenge, while 31% flagged study start-up. Headlands Research’s decision to join the SCRS Global Impact Partner program is a direct play for a seat at the table where those problems get worked on, not just described.
The Global Impact Partner Board puts Headlands alongside sponsors, CROs, and SCRS leadership in workstreams on site sustainability and best-practice development. For a network that has run more than 5,000 clinical trials across a range of therapeutic areas, the value is less about visibility and more about translating operational volume into policy input. SCRS represents over 12,000 sites in more than 75 countries, so the board conversations carry real weight when they feed back into how the broader industry structures site support and trial execution.
What makes this worth watching from a ClinOps angle is the structural position it creates. Most site networks interface with sponsors and CROs at the contract level. A dedicated board seat shifts that relationship upstream, into the conversations that shape enrollment expectations, amendment processes, and operational standards before any individual trial is designed. That is where site sustainability either gets built in or gets ignored.
The immediate consequence for Headlands is accountability in both directions: the company gains influence over industry norms, and it now has a formal obligation to represent site-level realities to stakeholders who often see sites as an execution variable rather than a design input. Whether that pressure produces measurable changes in how trials are structured at the site level is the thing to track as the workstreams produce outputs.
Source link: https://headlandsresearch.com/news/headlands-research-joins-scrs-global-impact-partner-program/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
